Empower Clinics Grows Revenues 130%, Patient Visits 125% And Becomes Cash Flow Positive

AGORACOM Small Cap CEO Interviews - A podcast by AGORACOM

Categories:

Sometimes, you just have to let the numbers speak for themselves.  With 165,000 patients, Empower Clinics (CBDT:CSE) (EPWCF:OTCQB) has a database that almost every medical cannabis and CBD company would  kill for … but then these numbers came in for the first two quarters: Revenues $USD 1.7M vs $745,000 = 130% Gain Patient Visits 12,400 vs 5,500 = 125% Gain CBDT has now delivered growth in 4 successive financial reports (Q4,  FY 2019, Q1 and Q2), so it is safe to say that superstar CEO Steve  McAuley can officially claim victory on the turnaround he inherited in  2019. But he is far from done. CBDT also just announced the potential acquisition of an 8,000 sq ft  lab in Dallas (they do everything big over there) that can process 2,000  COVID-19 tests per 8 hour shift.  At an average price of ~ $USD 90 per  test, the clinic could represent $USD 180,000 in revenue PER SHIFT.   However, until this acquisition closes, we’re not going to focus on it  too much – but that could happen as early as next week. Moreover, CBDT has to actually fill that capacity, which McAuley says  he is working on right now with some enterprise sized discussions  taking place as we write. Can he pull it off?  First consider what he  has already accomplished after inheriting a catastrophe of a company.   Secondly, McAuley, is Six Sigma certified under the quality initiative  of legendary GE (General Electric) Chairman Jack Welch. We’ve never seen  a Six Sigma certified CEO in the Canadian small cap markets. Never ….  which explains how McAuley has been able to guide Empower Clinics  through the most disruptive retail environment in recent history and  turn it into significant growth … and gives us optimism about this  acquisition. Watch this amazing interview. Watch this interview or listen by Podcast on Apple, Google, Spotify or your favourite podcaster.